Sun Young Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sun Young Lee has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Dimitrios Pollalis
USC Roski Eye Institute, Keck School of Medicine University of Southern California Los Angeles California USA
5 shared publicationsAmir I. Khan
Center for Stem Cell Biology and Engineering, Neuroscience Research Institute University of California Santa Barbara California USA
4 shared publicationsAshley K. Yeh
Department of Molecular Cellular and Developmental Biology University of California Santa Barbara California USA
4 shared publicationsBritney O. Pennington
Center for Stem Cell Biology and Engineering, Neuroscience Research Institute University of California Santa Barbara California USA
4 shared publicationsDennis O. Clegg
Center for Stem Cell Biology and Engineering, Neuroscience Research Institute University of California Santa Barbara California USA
4 shared publications- Dimitrios Pollalis
USC Ginsburg Institute of for Biomedical Therapeutics, University of Southern California, Los Angeles, CA 90033, USA
4 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (11)
Re: Chujo et al.: Photoreceptor Density-Dependent Kinetics of Geographic Atrophy Progression
- 1 September 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (11)
Open AccessRe: Chujo et al.: Photoreceptor Density-Dependent Kinetics of Geographic Atrophy Progression
- 16 February 2026
- Published by Taylor & Francis in Current Eye Research
- Vol. 51 (6) , 638
Author Response to the Letter on “Extracellular Vesicles as Tools to reestablish Ocular Immune Privilege”
- 16 February 2026
- Published by Taylor & Francis in Current Eye Research
- Vol. 51 (6) , 638
Author Response to the Letter on “Extracellular Vesicles as Tools to reestablish Ocular Immune Privilege”
- Open Access
- 13 February 2026
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 42, 102540
Ocular manifestations of STAT3 gain-of-function syndrome: A case of papillitis, retinitis, and retinal vasculitis
- 13 February 2026
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 42, 102540
Open AccessOcular manifestations of STAT3 gain-of-function syndrome: A case of papillitis, retinitis, and retinal vasculitis
- 1 December 2025
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 51 (12) , 1151-1152
Hemorrhagic capsular block syndrome after cataract surgery
An abstract is unavailable. This article is available as a PDF only.
- 1 December 2025
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 51 (12) , 1151-1152
Hemorrhagic capsular block syndrome after cataract surgery
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 5 November 2025
- Published by Taylor & Francis in Current Eye Research
- Vol. 50 (12) , 1297-1311
Cell Free Regenerative Extracellular Vesicle Therapy for Ocular Diseases
To assess the therapeutic potential of extracellular vesicles (EVs) derived from stem cells and ocular tissues as a cell-free alternative to traditional stem cell therapies for a broad spectrum of ocular diseases. A comprehensive literature review was performed, focusing on preclinical studies involving EVs derived from mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural progenitor cells, immune cells, and ocular-resident cells. Data were extracted on EV cellular origin, isolation methods, routes of administration, preclinical disease models, therapeutic outcomes, and proposed mechanisms of action. Registered clinical trials were also evaluated. EVs exhibited regenerative and immunomodulatory effects across a range of ocular conditions, including dry eye, uveitis, glaucoma, retinal degenerations, and optic neuropathies. Various cell sources have been explored for EV production, including MSCs, iPSCs, hESCs, retinal organoids, and other ocular tissue-resident cells. In addition, bioengineered EVs have been developed to modify surface properties or enhance therapeutic cargo. Reported mechanisms of action include miRNA-mediated gene regulation, immune modulation, and oxidative stress reduction. Several early-phase clinical trials are currently underway to translate these findings into human therapies. Stem cell-derived EVs represent a promising next-generation, cell-free regenerative therapy for ocular diseases. While preclinical data are promising, successful clinical translation will require optimal EV source selection, scalable and GMP-compliant production, identification of disease-relevant mechanisms of action, rigorous cargo characterization, and alignment with regulatory standards.
- 5 November 2025
- Published by Taylor & Francis in Current Eye Research
- Vol. 50 (12) , 1297-1311
Open AccessCell Free Regenerative Extracellular Vesicle Therapy for Ocular Diseases
To assess the therapeutic potential of extracellular vesicles (EVs) derived from stem cells and ocular tissues as a cell-free alternative to traditional stem cell therapies for a broad spectrum of ocular diseases. A comprehensive literature review was performed, focusing on preclinical studies involving EVs derived from mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural progenitor cells, immune cells, and ocular-resident cells. Data were extracted on EV cellular origin, isolation methods, routes of administration, preclinical disease models, therapeutic outcomes, and proposed mechanisms of action. Registered clinical trials were also evaluated. EVs exhibited regenerative and immunomodulatory effects across a range of ocular conditions, including dry eye, uveitis, glaucoma, retinal degenerations, and optic neuropathies. Various cell sources have been explored for EV production, including MSCs, iPSCs, hESCs, retinal organoids, and other ocular tissue-resident cells. In addition, bioengineered EVs have been developed to modify surface properties or enhance therapeutic cargo. Reported mechanisms of action include miRNA-mediated gene regulation, immune modulation, and oxidative stress reduction. Several early-phase clinical trials are currently underway to translate these findings into human therapies. Stem cell-derived EVs represent a promising next-generation, cell-free regenerative therapy for ocular diseases. While preclinical data are promising, successful clinical translation will require optimal EV source selection, scalable and GMP-compliant production, identification of disease-relevant mechanisms of action, rigorous cargo characterization, and alignment with regulatory standards.
- Open Access
- 12 December 2024
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 13 (12) , e70023
A perspective from the National Eye Institute Extracellular Vesicle Workshop: Gaps, needs, and opportunities for studies of extracellular vesicles in vision research
With an evolving understanding and new discoveries in extracellular vesicle (EV) biology and their implications in health and disease, the significant diagnostic and therapeutic potential of EVs for vision research has gained recognition. In 2021, the National Eye Institute (NEI) unveiled its Strategic Plan titled ‘Vision for the Future (2021–2025),’ which listed EV research as a priority within the domain of Regenerative Medicine, a pivotal area outlined in the Plan. In alignment with this prioritization, NEI organized a workshop inviting twenty experts from within and beyond the visual system. The workshop aimed to review current knowledge in EV research and explore gaps, needs and opportunities for EV research in the eye, including EV biology and applications of EVs in diagnosis, therapy and prognosis within the visual system. This perspective encapsulates the workshop's deliberations, highlighting the current landscape and potential implications of EV research in advancing eye health and addressing visual diseases.
- 12 December 2024
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 13 (12) , e70023
Open AccessA perspective from the National Eye Institute Extracellular Vesicle Workshop: Gaps, needs, and opportunities for studies of extracellular vesicles in vision research
With an evolving understanding and new discoveries in extracellular vesicle (EV) biology and their implications in health and disease, the significant diagnostic and therapeutic potential of EVs for vision research has gained recognition. In 2021, the National Eye Institute (NEI) unveiled its Strategic Plan titled ‘Vision for the Future (2021–2025),’ which listed EV research as a priority within the domain of Regenerative Medicine, a pivotal area outlined in the Plan. In alignment with this prioritization, NEI organized a workshop inviting twenty experts from within and beyond the visual system. The workshop aimed to review current knowledge in EV research and explore gaps, needs and opportunities for EV research in the eye, including EV biology and applications of EVs in diagnosis, therapy and prognosis within the visual system. This perspective encapsulates the workshop's deliberations, highlighting the current landscape and potential implications of EV research in advancing eye health and addressing visual diseases.
- Open Access
- 13 September 2024
- Published by Wiley in Journal of Extracellular Biology
- Vol. 3 (9) , e70001
Dynamics of microRNA secreted via extracellular vesicles during the maturation of embryonic stem cell‐derived retinal pigment epithelium
Retinal pigment epithelial (RPE) cells are exclusive to the retina, critically multifunctional in maintaining the visual functions and health of photoreceptors and the retina. Despite their vital functions throughout lifetime, RPE cells lack regenerative capacity, rendering them vulnerable which can lead to degenerative retinal diseases. With advancements in stem cell technology enabling the differentiation of functional cells from pluripotent stem cells and leveraging the robust autocrine and paracrine functions of RPE cells, extracellular vesicles (EVs) secreted by RPE cells hold significant therapeutic potential in supplementing RPE cell activity. While previous research has primarily focused on the trophic factors secreted by RPE cells, there is a lack of studies investigating miRNA, which serves as a master regulator of gene expression. Profiling and defining the functional role of miRNA contained within RPE‐secreted EVs is critical as it constitutes a necessary step in identifying the optimal phenotype of the EV‐secreting cell and understanding the biological cargo of EVs to develop EV‐based therapeutics. In this study, we present a comprehensive profile of miRNA in small extracellular vesicles (sEVs) secreted during RPE maturation following differentiation from human embryonic stem cells (hESCs); early‐stage hESC‐RPE (20–21 days in culture), mid‐stage hESC‐RPE (30–31 days in culture) and late‐stage hESC‐RPE (60–61 days in culture). This exploration is essential for ongoing efforts to develop and optimize EV‐based intraocular therapeutics utilizing RPE‐secreted EVs, which may significantly impact the function of dysfunctional RPE cells in retinal diseases.
- 13 September 2024
- Published by Wiley in Journal of Extracellular Biology
- Vol. 3 (9) , e70001
Open AccessDynamics of microRNA secreted via extracellular vesicles during the maturation of embryonic stem cell‐derived retinal pigment epithelium
Retinal pigment epithelial (RPE) cells are exclusive to the retina, critically multifunctional in maintaining the visual functions and health of photoreceptors and the retina. Despite their vital functions throughout lifetime, RPE cells lack regenerative capacity, rendering them vulnerable which can lead to degenerative retinal diseases. With advancements in stem cell technology enabling the differentiation of functional cells from pluripotent stem cells and leveraging the robust autocrine and paracrine functions of RPE cells, extracellular vesicles (EVs) secreted by RPE cells hold significant therapeutic potential in supplementing RPE cell activity. While previous research has primarily focused on the trophic factors secreted by RPE cells, there is a lack of studies investigating miRNA, which serves as a master regulator of gene expression. Profiling and defining the functional role of miRNA contained within RPE‐secreted EVs is critical as it constitutes a necessary step in identifying the optimal phenotype of the EV‐secreting cell and understanding the biological cargo of EVs to develop EV‐based therapeutics. In this study, we present a comprehensive profile of miRNA in small extracellular vesicles (sEVs) secreted during RPE maturation following differentiation from human embryonic stem cells (hESCs); early‐stage hESC‐RPE (20–21 days in culture), mid‐stage hESC‐RPE (30–31 days in culture) and late‐stage hESC‐RPE (60–61 days in culture). This exploration is essential for ongoing efforts to develop and optimize EV‐based intraocular therapeutics utilizing RPE‐secreted EVs, which may significantly impact the function of dysfunctional RPE cells in retinal diseases.
- Open Access
- 12 September 2024
- Published by Elsevier in Ophthalmology Science
- Vol. 5 (1) , 100619
An Eye on Extracellular Vesicles: Trends and Clinical Translations in Vision Research
- 12 September 2024
- Published by Elsevier in Ophthalmology Science
- Vol. 5 (1) , 100619
Open AccessAn Eye on Extracellular Vesicles: Trends and Clinical Translations in Vision Research
- Open Access
Rescuing Photoreceptors in RPE Dysfunction-Driven Retinal Degeneration: The Role of Small Extracellular Vesicles Secreted from Retinal Pigment Epithelium
Dysfunction of the retinal pigment epithelium (RPE) is a common shared pathology in major degenerative retinal diseases despite variations in the primary etiologies of each disease. Due to their demanding and indispensable functional roles throughout the lifetime, RPE cells are vulnerable to genetic predisposition, external stress, and aging processes. Building upon recent advancements in stem cell technology for differentiating healthy RPE cells and recognizing the significant roles of small extracellular vesicles (sEV) in cellular paracrine and autocrine actions, we investigated the hypothesis that the RPE-secreted sEV alone can restore essential RPE functions and rescue photoreceptors in RPE dysfunction-driven retinal degeneration. Our findings support the rationale for developing intravitreal treatment of sEV. We demonstrate that intravitreally delivered sEV effectively penetrate the full thickness of the retina. Xenogenic intraocular administration of human-derived EVs did not induce acute immune reactions in rodents. sEV derived from human embryonic stem cell (hESC)-derived fully differentiated RPE cells, but not sEV-depleted conditioned cell culture media (CCM minus sEV), rescued photoreceptors and their function in a Royal College of Surgeons (RCS) rat model. This model is characterized by photoreceptor death and retinal degeneration resulting from a mutation in the MerTK gene in RPE cells. From the bulk RNA sequencing study, we identified 447 differently expressed genes in the retina after hESC-RPE-sEV treatment compared with the untreated control. Furthermore, 394 out of 447 genes (88%) showed a reversal in expression toward the healthy state in Long-Evans (LE) rats after treatment compared to the diseased state. Particularly, detrimental alterations in gene expression in RCS rats, including essential RPE functions such as phototransduction, vitamin A metabolism, and lipid metabolism were partially reversed. Defective photoreceptor outer segment engulfment due to intrinsic MerTK mutation was partially ameliorated. These findings suggest that RPE-secreted sEV may play a functional role similar to that of RPE cells. Our study justifies further exploration to fully unlock future therapeutic interventions with sEV in a broad array of degenerative retinal diseases.
Open AccessRescuing Photoreceptors in RPE Dysfunction-Driven Retinal Degeneration: The Role of Small Extracellular Vesicles Secreted from Retinal Pigment Epithelium
Dysfunction of the retinal pigment epithelium (RPE) is a common shared pathology in major degenerative retinal diseases despite variations in the primary etiologies of each disease. Due to their demanding and indispensable functional roles throughout the lifetime, RPE cells are vulnerable to genetic predisposition, external stress, and aging processes. Building upon recent advancements in stem cell technology for differentiating healthy RPE cells and recognizing the significant roles of small extracellular vesicles (sEV) in cellular paracrine and autocrine actions, we investigated the hypothesis that the RPE-secreted sEV alone can restore essential RPE functions and rescue photoreceptors in RPE dysfunction-driven retinal degeneration. Our findings support the rationale for developing intravitreal treatment of sEV. We demonstrate that intravitreally delivered sEV effectively penetrate the full thickness of the retina. Xenogenic intraocular administration of human-derived EVs did not induce acute immune reactions in rodents. sEV derived from human embryonic stem cell (hESC)-derived fully differentiated RPE cells, but not sEV-depleted conditioned cell culture media (CCM minus sEV), rescued photoreceptors and their function in a Royal College of Surgeons (RCS) rat model. This model is characterized by photoreceptor death and retinal degeneration resulting from a mutation in the MerTK gene in RPE cells. From the bulk RNA sequencing study, we identified 447 differently expressed genes in the retina after hESC-RPE-sEV treatment compared with the untreated control. Furthermore, 394 out of 447 genes (88%) showed a reversal in expression toward the healthy state in Long-Evans (LE) rats after treatment compared to the diseased state. Particularly, detrimental alterations in gene expression in RCS rats, including essential RPE functions such as phototransduction, vitamin A metabolism, and lipid metabolism were partially reversed. Defective photoreceptor outer segment engulfment due to intrinsic MerTK mutation was partially ameliorated. These findings suggest that RPE-secreted sEV may play a functional role similar to that of RPE cells. Our study justifies further exploration to fully unlock future therapeutic interventions with sEV in a broad array of degenerative retinal diseases.
- Open Access
Dynamics of MicroRNA Secreted via Extracellular Vesicles During the Maturation of Embryonic Stem Cell-Derived Retinal Pigment Epithelium
Retinal pigment epithelium (RPE) cells are exclusive to the retina, critically multifunctional in maintaining the visual functions and health of photoreceptors and the retina. Despite their vital functions throughout lifetime, RPE cells lack regenerative capacity, rendering them vulnerable and central to degenerative retinal diseases. With advancements in stem cell technology enabling the differentiation of functional cells from pluripotent stem cells and leveraging the robust autocrine and paracrine functions of RPE cells, extracellular vesicles (EVs) secreted by RPE cells hold significant therapeutic potential in supplementing RPE cell activity. While previous research has primarily focused on the trophic factors secreted by RPE cells, there is a lack of studies investigating miRNA, which serves as a master regulator of gene expression. Profiling and defining the functional role of miRNA contained within RPE-secreted EVs is critical as it constitutes a necessary step in identifying the optimal phenotype of the EV secreting cell and understanding biological cargo of EVs to develop EV-based therapeutics. In this study, we present a comprehensive profile of miRNA in small extracellular vesicles (sEV) secreted during RPE maturation following differentiation from human embryonic stem cells (hESCs). This exploration is essential for ongoing efforts to develop and optimize EV-based intraocular therapeutics utilizing RPE-secreted EVs, which may significantly impact the function of dysfunctional RPE cells.
Open AccessDynamics of MicroRNA Secreted via Extracellular Vesicles During the Maturation of Embryonic Stem Cell-Derived Retinal Pigment Epithelium
Retinal pigment epithelium (RPE) cells are exclusive to the retina, critically multifunctional in maintaining the visual functions and health of photoreceptors and the retina. Despite their vital functions throughout lifetime, RPE cells lack regenerative capacity, rendering them vulnerable and central to degenerative retinal diseases. With advancements in stem cell technology enabling the differentiation of functional cells from pluripotent stem cells and leveraging the robust autocrine and paracrine functions of RPE cells, extracellular vesicles (EVs) secreted by RPE cells hold significant therapeutic potential in supplementing RPE cell activity. While previous research has primarily focused on the trophic factors secreted by RPE cells, there is a lack of studies investigating miRNA, which serves as a master regulator of gene expression. Profiling and defining the functional role of miRNA contained within RPE-secreted EVs is critical as it constitutes a necessary step in identifying the optimal phenotype of the EV secreting cell and understanding biological cargo of EVs to develop EV-based therapeutics. In this study, we present a comprehensive profile of miRNA in small extracellular vesicles (sEV) secreted during RPE maturation following differentiation from human embryonic stem cells (hESCs). This exploration is essential for ongoing efforts to develop and optimize EV-based intraocular therapeutics utilizing RPE-secreted EVs, which may significantly impact the function of dysfunctional RPE cells.